ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Share Discussion Threads

Showing 51 to 74 of 37200 messages
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
07/8/2007
10:15
the 150k 'sell' is clearly a delayed buy
don't be fooled into selling.. :-)

andrbea
07/8/2007
10:15
Great piece andrea...It is starting to look better and better..Auto immunity test kits are big business. And take a look what the markets spend on this type of product,the european market alone is currently over £270 million...
power talker
07/8/2007
10:13
ANDRBEA, you beat me to it , Thanks ! looking good about time ! Lets hope that some PI's Hold on and dont sell to quick !
gadg3t
07/8/2007
10:07
some background

(Aug 7)

Omega, based in Alva, Clackmannanshire, supplies clinical tests for diseases such as syphilis, tuberculosis and dengue fever. The chief executive, Andrew Shepherd, said the acquisition of Genesis-CNS, which is based in Ely, Cambridgeshire, would "strengthen and diversify" his company's product line-up.

"The acquisition of Genesis-CNS is highly significant, as it is our first since joining AIM," he added. "We look forward to presenting this enhanced product range to our extensive distribution network spanning over 100 countries."


Shares in Omega were suspended last month at the company's request after it revealed it was in talks over a possible takeover.

Omega, which employs 22 staff against Genesis-CNS's 25-strong headcount, joined AIM last September following the reverse takeover of cash shell Quintessentially English.

The Scots firm said trading in the current year remained flat, but added it was confident of prospects for the enlarged group.

Michael Walker, who graduated in biochemistry at Strathclyde University and founded the Genesis business in 1994, is set to join the main board as a non-executive director.

Genesis-CNS has developed a range of in-vitro diagnostic test kits specialising in the areas of autoimmune disease, infectious disease and food intolerance.

The firm supplies its kits to hospital laboratories in 27 countries.

Worth some $440m (£217m) in 2004, the European market for autoimmune disease diagnostics is forecast to hit $700m by 2011.

Omega said its Cambridgeshire peer generated sales of almost £2.2m in the year to the end of October 2006.

A shareholder vote on the acquisition and share consolidation is due to take place in Edinburgh on 30 August.

andrbea
07/8/2007
09:59
smiler not at all.i paid 0.9p first 150k then 1.p for the rest, you can still buy around a penny...This is a multi bagger..Just watch, the aqcuisition is fantastic.
power talker
07/8/2007
09:56
Thinking of getting some more, Think I have missed the boat up 33% already ??? any thoughts how high this could go say in 2/3 months ?
smiler 0
07/8/2007
09:53
Can still buy online at 1p..:) Not for much longer..
power talker
07/8/2007
09:50
It is estimated that the total European autoimmune disease diagnostics market
was worth US$440 million in 2004 and it is predicted that it may reach almost
US$700 million by 2011.


Ability to increase the routes to market:

The Genesis-CNS distribution network only extends to 27 countries whereas
Omega's extends to over 100 countries. The Directors intend to increase sales of
Genesis-CNS and Omega's products by cross-selling them into the combined
distribution network.

power talker
07/8/2007
09:47
Up we go again....
power talker
07/8/2007
09:46
Level 2 is looking good, all mms moving upwards on both the bid and offer...Should tick over again soon.
power talker
07/8/2007
09:45
Gadg...I thought i would get as many as i could while cheap..
power talker
07/8/2007
09:44
Can still buy 150k online..I would get some, once the overhangs gone these will be difficult to buy...Limited number in issue...Excellent news and not yet fully on the radar, that will change shortly..
power talker
07/8/2007
09:43
YOU HAVE MORE THAN ME NOW !!!! ; )
gadg3t
07/8/2007
09:42
In for another 140 k...Thats me with 600k now...Will be 3p by close..
power talker
07/8/2007
09:39
no worries andrea...This will be well through 100% by close...Genesis is profitable and operates in over 100 countrys...Big growth potential..And the 1-40 will make these like gold dust..
power talker
07/8/2007
09:36
Well As you can see I have always been positive , Things could start to move Now, Its good to see some action !! UP we GO
gadg3t
07/8/2007
09:36
did a tiny buy to be part of the climb
and offer ticked up

2 MM buys at full whack are encouraging.

tks for alerting us P-Talker :-)

andrbea
07/8/2007
09:36
INFORMATION ON GENESIS-CNS

Genesis and CNS are established businesses in the medical diagnostics industry
which develop, produce and sell a range of IVD tests kits specialising in the
areas of autoimmune disease, infectious disease and food intolerance. The
acquisition of Genesis-CNS is in line with Omega's strategy of focusing on
selected acquisitions of niche players in the IVD market. Genesis-CNS has the
following characteristics which make it an attractive acquisition for the
Company:

- Growing, profitable, cash-generative

- Operating in growth markets

- Ability to increase the routes to market

- Complementary product ranges

- Well established high quality management team


Growing, profitable, cash-generative:

Over the three years to the year ended 31 October 2006 Genesis-CNS sales have
grown to approximately #2,192,000 (including intercompany sales of approximately
#78,000) for the 2005/6 financial year. For the year ended 31 October 2006
Genesis recorded a profit before tax of #238,103 and generated an operating cash
surplus of #259,117. As at 31 October 2006, Genesis had net assets of #885,204.
For the year ended 31 October 2006 CNS recorded a profit before tax of #79,474
and generated an operating cash surplus of #64,738. As at 31 October 2006, CNS
had net assets of #121,414.

power talker
07/8/2007
09:34
Just got another 100k...This is going to really rocket when the market susses out its potential.
power talker
07/8/2007
09:31
Exactly rheiner...This is a multi multi bagger.
power talker
07/8/2007
09:28
1 for 40 consolidation is on the way. This will leave so few shares in issue that in future this share is sure to move about with quite small trades.
rheiner
07/8/2007
09:27
Moving up nicely now...Can hardly buy any online...MMs expected this to rocket yesterday..could not buy any till after 1pm..

I jumped straight in this am..Got 350k..Wait for blast off.

power talker
07/8/2007
09:24
"The acquisition of Genesis-CNS is highly significant as it is our first since
joining AIM in September 2006. Genesis and CNS are growing, profitable and cash
generative businesses operating in the growth markets of Autoimmune Disease and
Food Intolerance testing. They also have proven new technologies which will
strengthen and diversify the Omega product offering.

"We look forward to presenting this enhanced product range to our extensive
distribution network spanning over 100 countries."

power talker
07/8/2007
09:23
Buy limits down to just 5k...look at the news yesterday..BRILLIANt
power talker
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1